- The NIH is on track to issue up to 40% fewer new grants this fiscal year due to a staffing crisis.
- The agency has shifted focus to processing only mandated grant renewals, effectively freezing new research initiatives.
- The staffing shortfall threatens to stall progress in areas like cancer therapeutics and neurodegenerative disease.
- Over 50,000 researchers annually depend on NIH funding to launch studies and sustain university labs.
- The staffing crisis raises alarms across the U.S. research enterprise and may lead to project delays and career stagnation.
The National Institutes of Health (NIH), the world’s largest public funder of biomedical research, is on track to issue up to 40% fewer new grants this fiscal year due to an unprecedented staffing crisis. With some divisions operating at less than half their required workforce, the agency has quietly shifted focus to processing only mandated grant renewals, effectively freezing new research initiatives. This contraction threatens to stall progress in areas from cancer therapeutics to neurodegenerative disease, and comes at a time when global scientific competition—particularly with China—is intensifying. Over 50,000 researchers annually depend on NIH funding to launch studies, hire staff, and sustain university labs. Now, many face project delays, career stagnation, or the likelihood of exiting academic science altogether, raising alarms across the U.S. research enterprise.
\n
Why the NIH Workforce Is at a Breaking Point
\n
The current staffing shortfall stems from a confluence of budget constraints, hiring freezes, and rising attrition across key NIH institutes, including the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI). While Congress has maintained flat funding for administrative operations, the volume of grant applications has surged by nearly 18% over the past five years, driven by expanding research fields like genomics and immunotherapy. Meanwhile, senior scientific review officers—essential for evaluating grant proposals—have left in droves, citing burnout and stagnant salaries. Recruitment efforts have faltered due to lengthy federal hiring processes and competition from private-sector biotech firms offering higher pay and faster advancement. The NIH’s Office of Extramural Research confirmed in internal memos that several study sections responsible for peer review are now unable to convene quorums, delaying decisions by six months or more. Without immediate intervention, experts warn the U.S. could lose its leadership in life sciences innovation.
\n
What Units Are Most Affected and Who’s Left Waiting
\n
The National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Mental Health (NIMH) are among the hardest hit, with some divisions reporting vacancy rates exceeding 45%. These institutes oversee critical research into cardiovascular disease, respiratory conditions, and psychiatric disorders—areas where timely innovation can save thousands of lives annually. As a result, new R01 grants, the cornerstone of investigator-initiated research, have been sharply curtailed. Early-career scientists, particularly those seeking their first major award through the NIH’s R01 or R21 mechanisms, are disproportionately affected. According to the Association of American Medical Colleges, nearly 60% of early-stage investigators rely solely on NIH funding to launch independent careers. With fewer new grants issued, universities are halting lab expansions and delaying faculty hires, creating a ripple effect across academic medicine. Some researchers have already begun redirecting proposals to private foundations or seeking collaborations abroad.
\n
Analyzing the Root Causes and Systemic Risks
\n
The staffing crisis reflects deeper structural challenges in how the U.S. supports its scientific infrastructure. Unlike research grants, administrative and personnel budgets at the NIH have not kept pace with inflation or workload growth. Between 2010 and 2025, the number of grant applications reviewed annually increased from 53,000 to over 62,000, yet the extramural staff count declined by 12%, according to NIH budget data. Moreover, the average time to process a grant has ballooned from four months to nearly nine. This inefficiency stems from overreliance on temporary contractors and a lack of investment in digital review systems. Experts point to a 2023 Nature investigation revealing that NIH program officers now manage twice as many grants as they did a decade ago. The consequence is not just delayed funding, but diminished scientific rigor—overworked reviewers may miss transformative proposals buried in the backlog. Without reform, the U.S. risks systemic erosion of its research pipeline.
\n
Who Bears the Cost of Delayed Discovery
\n
The impact of reduced grant issuance extends far beyond individual labs. Patients awaiting new therapies, particularly in oncology and rare diseases, may face years of delayed treatments. Biotech startups spun out of academic research rely on NIH grants to attract venture capital; stalled funding could dry up early-stage investment. Universities, which depend on indirect cost reimbursements from NIH awards to maintain facilities and core labs, may face budget shortfalls. International collaborators are also affected, as U.S. researchers lead or co-lead over 70% of global biomedical publications. Countries like Germany and South Korea are already expanding their research budgets, capitalizing on American stagnation. For early-career scientists, especially women and underrepresented minorities who already face barriers in academia, the missed opportunity could be career-ending. The long-term cost? A weakened U.S. position in global science and a slower pace of medical progress.
\n
Expert Perspectives
\n
Opinions are divided on how best to respond. Dr. Helen Nguyen, a science policy analyst at the Federation of American Scientists, argues that Congress must approve targeted funding to boost NIH administrative capacity. “You can’t run a $48 billion research enterprise on a skeleton crew,” she stated in a recent briefing. Others, like Dr. Rajiv Patel of the Brookings Institution, caution against quick fixes, warning that simply hiring more staff without modernizing workflows could compound inefficiencies. “The NIH needs not just people, but smarter systems,” Patel said. Some propose outsourcing peer review to academic consortia or adopting AI-assisted triage tools, though concerns about bias and transparency remain.
\n
Looking ahead, the NIH is expected to request a dedicated administrative supplement in the next federal budget cycle. However, with an election year looming and fiscal pressures mounting, approval is uncertain. The agency may also pilot automated workflows and expand remote review panels to ease the burden. Ultimately, the resolution will hinge on whether policymakers recognize that sustaining scientific leadership requires investing not just in research, but in the infrastructure that makes it possible. The next 12 months will be critical in determining whether the U.S. can reverse its research slowdown—or watch its innovation edge erode.
Source: Nature